Immunogenicity of GSK Bio's HPV Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age - Related Studies

Immunogenicity of GSK Bio's HPV Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age

This study has been completed.

Study NCT00423046. Last updated on October 9, 2008. Information provided by GlaxoSmithKline

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Cervical Cancer
		Papillomavirus Infection

2	Additional conditions recognized in this trial
		Infection
		Papillomavirus Infections
		Uterine Cervical Neoplasms

3	More general conditions related to this trial
		DNA Virus Infections
		Genital Diseases, Female
		Genital Neoplasms, Female
		Neoplasms
		Neoplasms by Site
		Tumor Virus Infections
		Urogenital Neoplasms
		Uterine Cervical Diseases
		Uterine Diseases
		Uterine Neoplasms
		Virus Diseases

4	Interventions listed in this trial
		HPV-16/18 L1/AS04 (580299)

5	Sponsors listed in this trial
		GlaxoSmithKline